254 (PB242): HMPL-500, a potent and selective EZH1/EZH2 dual inhibitor, demonstrates superior anti-tumor activity in preclinical models of hematological malignancies and solid tumors
Liang Ge, Wei Su, Weidong Xue, Qian Ding(Guiyang College of Traditional Chinese Medicine), Shaohua Chen(Institute of Urban Environment), Jian Wang(Wenzhou Medical University), Tiejun Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Ziqi Gao, Yang Sai, Ying Ren(China Medical University), H. Yu(East China Normal University), Alex Jiang, Ning Yang(First Affiliated Hospital of Hebei Medical University), Yanyan Zhang(Shanghai University of Traditional Chinese Medicine)
Cited by 0
Related Papers
Regulation of cellular iron metabolism
|Biochemical Journal|2011|964
Inhibition of neuronal ferroptosis protects hemorrhagic brain
|JCI Insight|2017|702
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
|Signal Transduction and Targeted Therapy|2023|457
Recent Advanced Technologies for the Characterization of Xenobiotic-Degrading Microorganisms and Microbial Communities
|Frontiers in Bioengineering and Biotechnology|2021|311
UCHL1 is a Parkinson's disease susceptibility gene
|Annals of Neurology|2004|266